DocMorris Achieves Over 40% Growth in Rx Revenue and Expands its Health Ecosystem

In the first half of 2025, DocMorris AG reported a significant 43.5% growth in its prescription (Rx) revenue, with total revenue increasing by 10.2%, reaching CHF 572.1 million. This growth was supported by advancements such as the launch of the AI-based DocMorris Assistant and a substantial increase in the number of active customers.

TeleClinic, a service under DocMorris, saw its revenue soar by over 150% in the same period, further integrating telemedicine into Germany's healthcare standard. The expansion comes amid structural EBITDA improvements and a focus on sustainable profitability, as noted by CFO Daniel Wüest.

Despite challenges like fewer working days and changes in brand offerings, non-Rx revenue still marked a modest increase. The recent Federal Court of Justice ruling favorable to prescription bonuses has also strengthened DocMorris's competitive edge in the market.